Highly painful in nature, inflammatory bowel diseases (IBD) consisting of Crohn’s and ulcerative colitis are caused by dysregulation of the immune system leading to intestinal inflammation and microbial changes. Numerous studies highlight alterations in gut microbiota and their metabolites with adverse outcomes in cancer, IBD, neurological disorders, obesity, and diabetes. Now, a study from researchers at the University of Louisville shows a microbial metabolite, Urolithin A, derived from a compound found in berries and pomegranates, can reduce and protect against IBD. The team has determined Urolithin A and its synthetic counterpart, UAS03, can ease IBD by increasing proteins capable of tightening epithelial cell junctions in the gut as well as reducing gut inflammation in animal models. The opensource study is published in the journal Nature Communications.
Previous studies show the microbiota and their metabolites are in close proximity to the gut epithelium, a barrier consisting of a single cell-layer maintained by tight junction proteins responsible for separating host components from the external environment. Levels of tight junction proteins are significantly reduced under IBD leading to increased gut permeability to noxious substances resulting in inflammatory responses. However, the functional dynamics of microbiota and their metabolites in IBD are unknown. The current study shows how Urolithin A and its synthetic counterpart, UAS03, reduce inflammation, restore gut barrier integrity, and protect against colitis.
The current study shows Urolithin A, a microbial metabolite derived from polyphenolics of berries and pomegranate fruits, and its synthetic analog, UAS03, significantly enhance gut barrier function and inhibit unwarranted inflammation in mice. Results show Urolithin A and UAS03 exert their barrier functions through activation of aryl hydrocarbon receptor-nuclear factor erythroid 2–related factor 2-dependent pathways to upregulate epithelial tight junction proteins. Data findings show treatment with these compounds lessen colitis symptoms in preclinical models by remedying barrier dysfunction and reducing inflammation.
The lab states their results highlight how microbial metabolites provide two-pronged beneficial activities at gut epithelium by enhancing barrier functions and reducing inflammation to protect from colonic diseases. They go on to add oral treatment with Urolithin A/UAS03 significantly alleviates systemic inflammation and colitis in an animal model suggesting potential therapeutic applications for the treatment of IBD.
The team surmises their data shows Urolithin A, a microbial metabolite derived from pomegranate fruits, and its analog, UAS03, ease IBDs by enhancing gut barrier function and reducing inflammation. For the future, the researchers state Urolithin A/UAS03 could be efficacious in IBD-related diseases, and may also have implications in other disorders involving barrier dysfunction and inflammation.
Source: University of Louisville
Get Healthinnovations delivered to your inbox:
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.